MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$14.72 USD
-0.44 (-2.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.93 +0.21 (1.43%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
INKT 14.72 -0.44(-2.90%)
Will INKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for INKT
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report | INKT ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
INKT: Analyst Downgrades MiNK Therapeutics to Neutral | INKT Stock News
MiNK Therapeutics (INKT) Downgraded to Neutral Amidst Valuation Concerns | INKT Stock News
MiNK Therapeutics (INKT) Downgraded by Analyst with Price Target Set | INKT Stock News